Skip to main content

Table 2 Baseline characteristics of non-valvular AF patients with DM after propensity score-based stabilized weights

From: Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants

 NOACsNOACs (A + D+R + E) (n = 20,967)Warfarin (n = 5812)ASMD
Apixaban n = 3249Dabigatran n = 6531Edoxaban n = 1389Rivaroxaban n = 9798NOACs vs. Warfarin
Age
 (Mean ± STD)75.6 ± 1073.5 ± 10.174.9 ± 9.975 ± 10.174.6 ± 10.174.5 ± 10.30.0118
 < 65499.76 (15.6%)1329.46 (20.3%)226.27 (16.8%)1619.19 (16.5%)3674.69 (17.6%)992.87 (17.8%)0.0129
 65–74923.58 (28.8%)2109.08 (32.3%)396.11 (29.4%)2894.27 (29.5%)6323.04 (30.3%)1658.22 (29.8%) 
 75–841163.61 (36.3%)2278.34 (34.9%)506.75 (37.7%)3656.43 (37.3%)7605.13 (36.4%)2030.02 (36.4%) 
 > 85620.66 (19.4%)818.07 (12.5%)216.63 (16.1%)1627.86 (16.6%)3283.22 (15.7%)891.61 (16%) 
Male1673.4 (52.2%)3788.91 (58%)730.05 (54.3%)5027.21 (51.3%)11,219.58 (53.7%)2981.44 (53.5%)0.0044
CHA2DS2-VASc (mean ± STD)4.6 ± 1.64.3 ± 1.64.4 ± 1.54.5 ± 1.74.5 ± 1.64.4 ± 1.60.0184
HAS-BLED (mean ± STD)3.2 ± 1.13 ± 1.13.1 ± 1.13.1 ± 1.13.1 ± 1.13 ± 1.10.0491
Hypertension2646.3 (82.5%)5147.03 (78.8%)1117.08 (83%)7823.89 (79.9%)16,734.29 (80.1%)4438.09 (79.6%)0.0122
Dyslipidemia2131.33 (66.5%)4013.75 (61.4%)964.54 (71.7%)6272.89 (64%)13,382.51 (64.1%)3545.77 (63.6%)0.0094
Chronic live disease448.27 (14%)836.45 (12.8%)211.38 (15.7%)1335.81 (13.6%)2831.92 (13.6%)745.06 (13.4%)0.0056
Chronic kidney disease884.71 (27.6%)1165.76 (17.8%)411.07 (30.6%)2318.11 (23.7%)4779.66 (22.9%)1290.66 (23.2%)0.0066
Chronic lung disease415.03 (12.9%)751.11 (11.5%)161.41 (12%)1403.16 (14.3%)2730.7 (13.1%)747.12 (13.4%)0.0099
Gout706.18 (22%)1152.6 (17.6%)317.42 (23.6%)1975.72 (20.2%)4151.94 (19.9%)1105.89 (19.8%)0.0009
Congestive heart failure461.45 (14.4%)721.17 (11%)174.76 (13%)1401.59 (14.3%)2758.96 (13.2%)770.92 (13.8%)0.0185
Chronic ischemic heart disease490.98 (15.3%)764.79 (11.7%)206.47 (15.3%)1457.45 (14.9%)2919.68 (14%)740.87 (13.3%)0.0202
Peripheral artery disease294.56 (9.2%)615.97 (9.4%)126.94 (9.4%)961.97 (9.8%)1999.44 (9.6%)531.89 (9.5%)0.0010
Stroke693.74 (21.6%)1497.7 (22.9%)189.25 (14.1%)2161.77 (22.1%)4542.45 (21.8%)1175.9 (21.1%)0.0160
Malignancy365.73 (11.4%)562.12 (8.6%)160.26 (11.9%)1055.43 (10.8%)2143.54 (10.3%)578.15 (10.4%)0.0037
PCI324.92 (10.1%)414.45 (6.3%)143.9 (10.7%)889.57 (9.1%)1772.84 (8.5%)459.64 (8.3%)0.0088
CABG35.34 (1.1%)30.41 (0.5%)10.85 (0.8%)90.42 (0.9%)167.02 (0.8%)44.51 (0.8%)0.0001
History of bleeding77.02 (2.4%)118.84 (1.8%)24.55 (1.8%)229.26 (2.3%)449.66 (2.2%)119.51 (2.1%)0.0006
Use of NSAIDs908.1 (28.3%)1567.68 (24%)380.44 (28.3%)2591.36 (26.5%)5447.58 (26.1%)1477.57 (26.5%)0.0099
Use of PPI470.21 (14.7%)662.62 (10.1%)177.39 (13.2%)1261.57 (12.9%)2571.79 (12.3%)690.04 (12.4%)0.0021
Use of H2 blocker1136.31 (35.4%)2108.48 (32.3%)452.75 (33.6%)3266.7 (33.3%)6964.24 (33.3%)1891.32 (33.9%)0.0127
Use of ACEI/ARB2179.74 (68%)4473.09 (68.5%)923.23 (68.6%)6739.93 (68.8%)14,315.99 (68.5%)3807.33 (68.3%)0.0048
Use of beta-blocker2033.15 (63.4%)3832.74 (58.7%)905.14 (67.3%)6041.78 (61.7%)12,812.82 (61.4%)3462.48 (62.1%)0.0164
Use of verapamil or diltiazem835.94 (26.1%)1555.98 (23.8%)260.29 (19.3%)2647.44 (27%)5299.65 (25.4%)1421.74 (25.5%)0.0032
Use of statin1524.64 (47.5%)2787.22 (42.7%)662.45 (49.2%)4428.17 (45.2%)9402.48 (45%)2467.58 (44.3%)0.0150
Use of APT557.85 (17.4%)1634.37 (25%)163.4 (12.1%)2288.62 (23.4%)4644.24 (22.2%)1275.11 (22.9%)0.0156
Use of metformin1464.25 (45.7%)3276.26 (50.1%)551.96 (41%)4424.87 (45.2%)9717.34 (46.5%)2605.79 (46.8%)0.0047
Use of SU1213.44 (37.8%)2703.68 (41.4%)443.81 (33%)3613.42 (36.9%)7974.35 (38.2%)2150.56 (38.6%)0.0085
Use of glinide316.99 (9.9%)545.52 (8.4%)104.16 (7.7%)941.11 (9.6%)1907.78 (9.1%)524.66 (9.4%)0.0098
Use of acarbose327.99 (10.2%)675.87 (10.3%)110.92 (8.2%)954.94 (9.8%)2069.72 (9.9%)564.11 (10.1%)0.0072
Use of glitazone187.7 (5.9%)380.2 (5.8%)64.64 (4.8%)470.95 (4.8%)1103.49 (5.3%)294.35 (5.3%)0.0001
Use of insulin981.92 (30.6%)1499.29 (22.9%)316.6 (23.5%)2823.21 (28.8%)5621.01 (26.9%)1541.1 (27.7%)0.0168
Use of SGLT2i62.44 (2%)52.38 (0.8%)48.25 (3.6%)109.87 (1.1%)272.94 (1.3%)19.75 (0.4%)0.1057
  1. The abbreviations as in Table 1